



## Recent Advances and Challenges in Tuberculosis Research

Guest Editors:

### Dr. Jianjun Sun

Department of Biological  
Sciences, University of Texas at El  
Paso, 500 West University  
Avenue, El Paso, TX 79968, USA

### Dr. Supriyo Ray

Department of Natural Sciences,  
Bowie State University, 14000  
Jericho Park Rd, Bowie, MD  
20715, USA

Deadline for manuscript  
submissions:  
**closed (31 October 2022)**

### Message from the Guest Editors

Dear Colleagues,

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis* (Mtb) that mainly affects the lungs but can affect other organs as well. The disease became a new challenge in 1985 after the emergence of HIV. According to WHO in 2019, 1.4 million patients died due to TB and close to 2 million people died due to COVID-19 in the year 2020. TB persists in two disease forms, asymptomatic latent TB and symptomatic active TB. With the evolution of drug-resistant strains and extremely drug-resistant strains, the global control of TB has become increasingly challenging.

All research articles, reviews, minireviews, case reports, clinical cases, meta-analyses, and perspectives will be considered for publication after rigorous peer review.

Potential topics include but are not limited to the following:

- Co-infection with COVID-19 and TB;
- Mechanisms of intracellular survival of pathogenic mycobacteria;
- Immune responses to pathogenic mycobacteria;
- Mycobacterial regulation of cell death;
- Advances in vaccine development and therapeutics against tuberculosis.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Lawrence S. Young

Warwick Medical School,  
University of Warwick, Coventry  
CV4 7AL, UK

## Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

**Journal Rank:** JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

## Contact Us

Pathogens Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pathogens](http://mdpi.com/journal/pathogens)  
[pathogens@mdpi.com](mailto:pathogens@mdpi.com)  
[X@Pathogens\\_MDPI](https://twitter.com/Pathogens_MDPI)